This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.
Accept & Close- Study & Courses
-
University Schools
- University Schools
- Art, Architecture & Design
- Built Environment & Engineering
- Business
- Clinical & Applied Sciences
- Computing, Creative Technologies & Engineering
- Cultural Studies & Humanities
- Education
- Events, Tourism & Hospitality Management
- Film, Music & Performing Arts
- Health & Community Studies
- Law
- Social Sciences
- Sport
- University Life
- Research
- Business
- About Us
- Leeds Beckett Websites:
- Staff
- Current Students
- Quick Links (A-F)
- Quick Links (G-Z)
All Subjects
- Accounting Finance and Economics
- Architecture and Landscape Design
- Art and Design
- Business and Management
- Civil Engineering and Construction
- Computing and Engineering
- Creative Technologies
- Education
- English History and Media
- English Language Study
- English Language Teaching
- Events Management
- Film Music and Performing Arts
- Health
- Law
- Marketing PR and Journalism
- Politics and International Relations
- Social Sciences and Psychology
- Sport
- Surveying and Planning
- Tourism and Hospitality
Research
Dr Nathaniel Milton
- Home
- >
- Research
- >
- Staff Directory
- >
- Dr Nathaniel Milton
Dr Nathaniel Milton
Principal Lecturer
School of Clinical & Applied Sciences
0113 81 23612 N.G.Milton@leedsbeckett.ac.ukAbout Dr Nathaniel Milton
Nat has an international reputation in the Alzheimer's Drug Discovery research field. He is a Fellow of the Royal Society of Biology and part of the Biomedical Sciences team in the School of Clinical & Applied Sciences.
For the past 20 years Nat has led the Amyloid-Binding Peptides research group, which conducts research into the biochemical interactions of amyloid peptides and their role in Alzheimer's disease, Diabetes, Creutzfeldt-Jakob disease and oxidative stress responses. He has used molecular biology, biochemical and cell biology techniques to discover and characterize the mechanisms of neuroprotection of a number of compounds. He has teaching experience, at both undergraduate and postgraduate levels, in the areas of Physiology, Pharmacology, Clinical Biochemistry, Neuroscience and Entrepreneurship.
Nat is and entrepreneur and has filed patent applications, which were taken to the intention to grant stage in Europe. He has founded an in silico based company, Neurodelta Ltd and raised government funding for commercial research in the Alzheimer’s Drug Discovery area.
Current Teaching
- BSc and MSc Biomedical Sciences courses
Research Interests
The Amyloid-Binding Peptides research group is currently focused on the roles of endogenous cannabinoids and opioids in neuroprotection against toxic amyloid peptides. The group discovered neuroprotective properties of endocannabinoids against amyloid-ß in cell based models of Alzheimer's disease and has recently identified novel mechanisms of neuroprotection by endogenous cannabinoids.
The group has also shown that products of the KiSS-1 metastasis-suppressor gene, the Kisspeptin and Kissorphin peptides, specifically bind amyloid-ß, amylin plus prion protein peptides and are neuroprotective in vitro. KiSS-1 overexpression is also neuroprotective in vitro and acts via oxytocin/vasopressin and cyclooxygenase dependent mechanisms. The co-localization of Kisspeptin with amyloid-ß deposits in the pons region of Alzheimer's brain has recently been demonstrated. Co-localization of corticotropin-releasing hormone with amyloid-ß deposits and also co-localization of catalase with amyloid-ß deposits in the pons region of Alzheimer's brain has also been demonstrated.
Related News
-
University Life
-
Employability & Graduates
- Contact Us
-
+44 (0)113 812 0000
Contact Details
- Find Us
-
Leeds Beckett University
City Campus, Leeds
LS1 3HE
© 2018 Leeds Beckett University